Acquisition Teardown For Finance Modules

Reviewed by Fallon Han· Updated 2026-06-01 06:09:27.995

This conversation was generated using Cook'd AI's career assistant and reviewed by Fallon Han from our editorial team for accuracy.

I'm an MBA candidate in the US coming from healthcare operations, and I'm targeting a corporate development role at a strategic acquirer. Can we unpack how a company evaluates, closes, and absorbs an acquisition using a deal-teardown format? I want to connect target screening, integration risk, and post-close KPI tracking across the whole finance module.

Absolutely. Think of the acquisition process as one linked chain: screen the target, value the deal, finance and close it, then prove the thesis after close. In a corporate development interview, you want to show that you understand not just how to buy a company, but how to decide if it should be bought, how to avoid overpaying, and how to know whether it is working later. A good deal-teardown structure is: 1. Strategic fit - why this target helps the acquirer win 2. Financial fit - how the economics look before synergies 3. Execution risk - what can go wrong in diligence and integration 4. Post-close success metrics - how management will track value creation If you want, we can walk through each step as if you were presenting a real target to an investment committee.

Let's start with target screening. As someone from healthcare operations, I tend to think about process fit and service quality. How does a corporate development team decide whether a target is even worth deeper diligence, especially for a strategic buyer?

Great instinct. Target screening is basically the first filter for whether a deal deserves management attention. A strategic acquirer usually looks for three things: 1. Strategic overlap or adjacency - does the target strengthen market share, product breadth, geography, or customer access? 2. Synergy potential - can the acquirer reduce costs, cross-sell, or improve pricing power? 3. Risk profile - are there regulatory, customer concentration, cultural, or integration issues that could destroy value? From a healthcare operations lens, you can think about it like triage. Some targets look attractive because the service line matches the acquirer's capabilities, but if the operating model is too different, integration may be harder than the revenue upside is worth. A strong screening memo often answers: Why now, why us, why this target, and what could break?

That makes sense. Once the target passes screening, how should I think about valuation and the closing process together? I want to avoid treating them as separate topics.

You are right to connect them. In real deals, valuation and closing mechanics are tightly linked. Valuation answers: what is this business worth to us? Closing answers: how do we actually get to ownership at that price and on those terms? For valuation, a strategic buyer usually starts with standalone value and then adds expected synergies. The key point is that synergies should not be assumed lightly. They need a timing estimate, a cost to achieve them, and a probability-weighted view. For closing, the buyer thinks about: - Purchase price structure, such as cash, stock, or mix - Financing sources and leverage capacity - Required approvals, including board, antitrust, or other regulatory signoffs - Closing conditions and protections like reps, warranties, and indemnities If valuation is too aggressive, the deal may still close but create a bad outcome. If the closing process is weak, the best deal thesis can fail before day one. So a good corporate development answer shows how price, structure, and risk allocation all fit together.

Now let's say the deal closes. What integration risks should I focus on in the first 100 days, and how do I connect those risks back to the original deal thesis?

This is where a lot of candidates get generic, so be specific. The first 100 days are about preserving the value you paid for. The main risks are usually: - Customer retention risk: key accounts may leave if service changes too fast - Talent retention risk: operators and leaders from the target may exit - Systems and process risk: ERP, billing, reporting, and controls may not sync well - Culture and decision-rights risk: unclear ownership slows execution - Synergy timing risk: expected savings may arrive later than the model assumed To connect back to the deal thesis, ask: which assumptions made this acquisition attractive in the first place? If the thesis depended on cross-selling, then customer churn is a major red flag. If it depended on procurement savings, then integration of vendors and contracts matters most. A strong answer is not just listing risks. It explains which ones would actually invalidate the investment case and which ones are manageable with a good integration plan.

How would I track whether the acquisition is working after close? I want a KPI framework that sounds credible in a corporate development interview, not just generic revenue growth.

Use a layered KPI framework tied to the deal thesis. Start with three buckets: 1. Revenue KPIs - Retention of top customers - Cross-sell or upsell conversion - Price realization - New logo growth if the thesis includes expansion 2. Cost and synergy KPIs - Realized cost savings versus plan - Procurement savings - SG and A productivity - Integration costs versus budget 3. Operational KPIs - Margin by business line - Service levels or turnaround times - Employee retention in key roles - Working capital or cash conversion if relevant The key is to compare actual results against the original model and timeline. That shows discipline. For example, if synergy capture is ahead but customer retention is lagging, the deal may look good in the short run but be fragile. In an interview, you can say: I would track a handful of KPIs that directly tie to the deal thesis, measure them monthly in the first year, and escalate any variance that could threaten the return on invested capital.